Skip to main content
. 2023 Jun 22;2(3):100127. doi: 10.1016/j.jacig.2023.100127

Table II.

Comparison between characteristics and outcomes of patients diagnosed with FDEIA and non-FDEIA food anaphylaxis

Characteristic Food (n = 83) FDEIA (n = 55) Non-FDEIA (n = 28) P value
Male sex, no. (%) 41 (49.4) 28 (50.9) 13 (46.4) .699
 Age (y), median (range) 44 (20-86) 47 (23-86) 38 (20-67) .096
 Age at first episode (y) 35 (1-80) 38 (15-80) 31 (1-62) .046
 Delay in diagnosis (y) 3 (0-26) 3 (0-26) 3 (0-17) .383
 Smoker, no. (%) 8 (9.6) 4 (7.3) 4 (14.3) .433
 Asthma and/or COPD, no. (%) 26 (31.3) 6 (10.9) 10 (35.7) .007
 Hypertension, no. (%) 10 (12.0) 9 (16.4) 1 (3.6) .153
 History of chronic urticaria, no. (%) 16 (19.3) 20 (36.4) 6 (21.4) .165
Clinical presentation, no. (%)
 Mucocutaneous 81 (97.6) 54 (98.2) 27 (96.4) 1.000
 Cardiovascular 63 (75.9) 50 (90.9) 13 (46.4) <.001
 Respiratory 47 (56.6) 26 (47.3) 21 (75.0) .016
 Gastrointestinal 14 (16.9) 9 (16.4) 5 (17.9) 1.000
WAO systemic allergic reaction grade, no. (%) <.001
 Grade 3 13 (15.7) 1 (1.8) 12 (42.9)
 Grade 4 2 (2.4) 1 (1.8) 1 (3.6)
 Grade 5 68 (81.9) 53 (96.4) 15 (53.6)
Acute management, no. (%)
 Paired tryptase sample taken 24 (28.9) 16 (29.1) 8 (28.6) .961
 Significant elevation 19/24 (79.2) 13/16 (81.3) 6/8 (75.0) 1.000
 Adrenaline administered 45 (54.2) 30 (54.5) 15 (53.6) .933
 Discharged with AAI 47 (56.6) 30 (54.5) 17 (60.7) .592
After allergist review
 AAI prescribed, no. (%) 83 (100.0) 55 (100.0) 28 (100.0) N/A
 Recurrence, no. (%) 7 (8.4) 4 (7.3) 3 (10.7) .683
 Adrenaline administered, no. (%) 4 (4.8) 1 (1.8) 3 (10.7) .109
 Follow-up duration (y), median (range) 1.83 (0.20-5.69) 1.76 (0.20-5.69) 2.03 (0.20-3.97) .677

Boldface indicates statistical significance (P < .05).

COPD, Chronic obstructive pulmonary disease; NA, not available; WAO, World Allergy Organization.

In this classification, anaphylaxis includes only grade 3 to grade 5 reactions.